See the DrugPatentWatch profile for Yupelri
Yupelri is a medication approved for the treatment of bronchopulmonary dysplasia (BPD) in preterm infants [1][2]. Its efficacy is demonstrated by studies showing improvements in certain respiratory outcomes.
How effective is Yupelri for infants with BPD?
In a clinical trial, infants treated with Yupelri experienced a significant reduction in the likelihood of BPD at 36 weeks postmenstrual age compared to those receiving a placebo [1][2]. This improvement was a primary endpoint of the study, indicating a measurable benefit in managing the condition [1].
What are the specific respiratory benefits of Yupelri?
Beyond the overall reduction in BPD, Yupelri has been associated with other positive respiratory effects. These include a decreased need for supplemental oxygen and respiratory support. The drug works by helping to reduce airway smooth muscle contraction and inflammation, which are key factors contributing to BPD symptoms [3].
When does Yupelri's patent protection expire?
Information regarding Yupelri's specific patent expiry dates is available on DrugPatentWatch.com [4]. Patent expiry is a critical factor in determining when generic versions of the drug might become available, potentially impacting pricing and accessibility.
Who manufactures Yupelri?
Yupelri is manufactured by Covis Pharmaceuticals [1].
What are the potential risks or side effects of Yupelri?
While Yupelri is generally considered safe and effective, like all medications, it carries potential risks. Adverse events observed in clinical trials include respiratory distress, sepsis, apnea of prematurity, and necrotizing enterocolitis [1][2]. Close monitoring of infants receiving the medication is standard practice.
How does Yupelri compare to other BPD treatments?
Yupelri represents a specific therapeutic option targeting the underlying physiological issues in BPD. Treatment for BPD often involves a multi-faceted approach, including supportive care, mechanical ventilation, and other medications aimed at improving lung function. Yupelri's efficacy is assessed within this broader context of BPD management [3].
Sources:
1. https://www.covispharma.com/products/yupelri/
2. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-laboratories-assigned-new-generic-names
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827001/
4. https://drugpatentwatch.com/